Testosterone and Bone Density: The Mechanism

Osteoporosis is filed under women's health, and that filing costs men. Male bone loss starts later and runs slower, which sounds reassuring until you look at what happens after a hip fracture in an older man — outcomes are worse than in women, and the condition that preceded it was usually never screened for. Testosterone sits close to the centre of this, but not in the way most people assume. The hormone doing most of the work on male bone is estradiol, and testosterone's largest contribution is that it is the raw material for it.

Bone is a live account, not a fixed structure

Bone is continuously demolished and rebuilt. Osteoclasts resorb old bone; osteoblasts lay down new bone; osteocytes buried inside the matrix sense mechanical load and direct the process. Density is not a stored quantity — it is the running balance between two active rates.

That framing changes what "bone loss" means. Nothing is being taken away from a static structure. Resorption is simply outpacing formation, month after month, and the deficit compounds. Three inputs push the balance toward formation: mechanical loading, hormonal signalling, and enough substrate — calcium, vitamin D and protein — to build with. Aging shifts the balance the other way. Hypogonadism shifts it further.

The finding that reframes the whole topic

Separating testosterone from estradiol requires an unusual experiment, because in normal physiology one is continuously being converted into the other.

Researchers suppressed the natural hormone axis in healthy men, then added back testosterone at varying doses — with or without an aromatase inhibitor to block its conversion to estradiol. That separates the two hormones in a way ordinary observation cannot. Bone and body-composition effects tracked estradiol closely; blocking aromatisation removed protection even while testosterone itself was maintained (Finkelstein et al., N Engl J Med 2013). Longitudinal cohort work points the same way: estradiol tracks bone density change and fracture risk in older men more consistently than testosterone does (reproductive hormones and longitudinal BMD change, J Bone Miner Res 2015). The clinical literature on aromatase activity and bone loss converges on the same conclusion (Adv Clin Chem 2011).

The practical consequence is immediate and often ignored: a man on testosterone therapy whose estradiol is aggressively suppressed — usually with an aromatase inhibitor taken to avoid bloating or breast tenderness — may have an excellent testosterone number and a worse bone position than before he started. Estradiol in men is not a side effect to be minimised. It is a required hormone that happens to be made from testosterone.

What testosterone contributes directly

Testosterone is not merely a precursor. Androgen receptors are present on bone cells, and testosterone acts on them: supporting osteoblast differentiation and activity, restraining osteoclast-driven resorption, and improving how the whole system responds to mechanical loading signals. Periosteal bone growth — the expansion of bone width during development that gives male bone its greater cross-sectional strength — is substantially androgen-driven.

So both hormones matter, with different jobs. Testosterone contributes to bone size and directly to the remodelling balance; estradiol is the dominant regulator of how fast resorption proceeds. Losing either is a problem. Losing estradiol while replacing testosterone is a self-inflicted one.

Muscle is the third hormone

The strongest routine loading signal a bone receives is the pull of the muscle attached to it. That is why bone density tracks muscle mass so closely, why immobilisation causes rapid bone loss, and why the most bone-loaded sites are the ones under the most muscular tension.

This creates a compounding chain worth stating explicitly: testosterone supports muscle, muscle loads bone, loading signals formation. It is also why hormone optimisation without resistance training leaves most of the available benefit unclaimed — the hormonal signal tells bone it may build; mechanical load tells it where and how much.

The risk in untreated low testosterone

Hypogonadism roughly doubles to triples fracture risk in men — hip fractures in the region of two to three times higher, vertebral fractures two to four times, with wrist fractures also elevated. Risk is highest in older hypogonadal men, and vertebral fractures in particular are frequently silent, found incidentally on imaging ordered for something else.

Given that, bone density screening deserves consideration in men with confirmed low testosterone, especially older men or those with additional risk factors — long-term glucocorticoids, prior fragility fracture, low body weight, smoking, heavy alcohol use, or a family history.

What treatment actually shows — including the part usually left out

In men with low testosterone, treatment increases bone mineral density: broadly in the region of 3-7% at hip and spine over one to two years, with the largest gains in the most deficient men, plateauing at a higher density rather than climbing indefinitely. The randomised Bone Trial within the Testosterone Trials measured this with quantitative CT and found increases in volumetric bone density and estimated bone strength, most pronounced in trabecular bone of the spine (Snyder et al., JAMA Intern Med 2017).

Here is the part that is routinely omitted, and it should not be. Higher bone density has not been shown to translate into fewer fractures with testosterone treatment. A large randomised fracture study in men with hypogonadism reported fractures that were, if anything, more frequent in the testosterone group than in placebo (Snyder et al., N Engl J Med 2024). The finding was unexpected and the mechanism is not established.

Density and fracture are related but not interchangeable — fractures depend on bone quality, geometry and, heavily, on falling. Anyone whose stated reason for treatment is fracture prevention is entitled to know that this specific endpoint has not been demonstrated, and that a well-conducted trial pointed the other way.

The full bone strategy

Hormones are one input among several, and the others are not optional:

• Keep estradiol in physiologic range — do not suppress it to feel leaner
• Calcium 1,000-1,200 mg daily, from diet first, supplement only for the shortfall
• Vitamin D adequate — 25-OH above roughly 40 ng/mL is the commonly used target
• Protein around 1.6 g/kg, which supports both the bone matrix and the muscle that loads it
• Resistance training 2-3x per week, loaded and progressive; this is the non-negotiable one
• Weight-bearing impact where joints allow — bone responds to rate of loading, not just magnitude
• Balance and fall prevention, which is what actually prevents fractures in older men
• No smoking, alcohol moderate
• DEXA at baseline with an interval follow-up, so change is measured rather than assumed
• Established osteoporosis drugs where indicated — testosterone is not a substitute for them

Bottom line

Testosterone matters for male bone largely because it is the source of estradiol, and estradiol is the dominant bone-protective hormone in men as well as women. Untreated low testosterone raises fracture risk substantially. Treatment reliably raises bone mineral density, but the fracture endpoint has not been demonstrated and one large randomised study found more fractures on treatment — so density improvement should be described as what it is, not extrapolated into a promise. The parts of this that are not in doubt are the unglamorous ones: keep estradiol in range, load the skeleton with progressive resistance training, eat enough protein and calcium, keep vitamin D adequate, and do not fall.

Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.